ViewsML to Present New Research Demonstrating Effectiveness of Its Virtual Immunohistochemistry (vIHC) Platform at the 2026 AACR Annual Meeting

Company to highlight how its AI-powered platform is transforming biomarker detection

Vancouver, BC – April 16, 2026 – ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced it will present three posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA. ViewsML will demonstrate how its virtual biomarker staining platform gives clinicians and researchers deeper biomarker insights from a single H&E slide, without the time and cost of traditional staining, driving faster decisions and improved patient outcomes.

Poster Presentation Details

Abstract 0075/6 – From single H&E to virtual immunohistochemical biomarker staining in the lung tumor microenvironment
Co-Presenters: ViewsML, Dartmouth-Hitchcock Medical Center
Date/Time: Sunday, April 19, 2026, 2:00 – 5:00 p.m.
Session: PO.BCS01.06 - Digital Pathology 1

Abstract 4161/11 – Validation of the ViewsML vIHC platform for biomarker classification and intensity binning: A pilot collaboration with Histowiz’s PathologyMap platform
Co-Presenters: ViewsML, HistoWiz
Date/Time: Tuesday, April 21, 2026, 9:00 a.m. – 12 p.m.
Session: PO.BCS01.08 - Digital Pathology 3

Abstract 4155/5 - Development of a virtual Cyclin E1 biomarker using Deep Learning from H&E slides for predicting Cyclin E1 overexpression in gynecological malignancy
Co-presenters: Debiopharm International (lead presenter), ViewsML, Translational Medicine
Date/Time: Tuesday, April 21, 2026, 9:00 a.m. – 12:00 p.m.
Session: PO.BCS01.08 - Digital Pathology 3

Contact us to set up a meeting at the show, and/or visit us at AACR booth #1557.

About ViewsML
ViewsML is building the world’s first virtual biomarker library, an expanding platform of AI models designed to extract biomarker insights directly from routine pathology images. By virtualizing immunohistochemistry (IHC), a diagnostic process that has remained largely unchanged for decades, ViewsMLenables scientists and clinicians to analyze biomarker staining in minutes rather than the days to weeks required by traditional laboratory workflows.

The company’s technology delivers per-cell spatial biomarker insights from standard H&E slides, preserving scarce tissue samples while accelerating research, clinical trials, and patient care. Working with leading pharmaceutical companies, hospitals, and diagnostic labs, ViewsML is helping unlock the full biological value of existing pathology data and enabling a faster, more scalable path to precision medicine. To learn more, visit www.viewsml.com.

PR Contact
Public Relations and Marketing Communications
pr@viewsml.com